Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Triple Negative Breast Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm Metastasis 2Melanoma 2Lung Neoplasms 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myelomonocytic, Acute 2Leukemia, Myeloid, Acute 2Carcinoma, Renal Cell 2Urinary Bladder Neoplasms 1Recurrence 1Rectal Neoplasms 1Pinealoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Ovarian Diseases 1Neuroendocrine Tumors 1Myeloproliferative Disorders 1Mammary Neoplasms, Animal 1Lymphoma 1Leukemia, Promyelocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Kidney Neoplasms 1Hodgkin Disease 1Fallopian Tube Neoplasms 1FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma 1

Interventions

entinostat 1avelumab 1NUC-1031 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Ovarian Diseases × entinostat × Clear all
NCT02915523 2024-01-10

Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer

Syndax Pharmaceuticals

Phase 1/2 Completed
140 enrolled 25 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Diseases, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡